Moyad M - Search Results

1

Primary causes of death after permanent prostate brachytherapy.

Bittner N, Merrick GS, Galbreath RW, Butler WM, Wallner KE, Allen ZA, Brammer SG, Moyad M. Bittner N, et al. Among authors: moyad m. Int J Radiat Oncol Biol Phys. 2008 Oct 1;72(2):433-40. doi: 10.1016/j.ijrobp.2008.02.013. Epub 2008 Apr 28. Int J Radiat Oncol Biol Phys. 2008. PMID: 18448268

2

Statins, especially atorvastatin, may favorably influence clinical presentation and biochemical progression-free survival after brachytherapy for clinically localized prostate cancer.

Moyad MA, Merrick GS, Butler WM, Wallner KE, Galbreath RW, Kurko B, Adamovich E. Moyad MA, et al. Urology. 2005 Dec;66(6):1150-4. doi: 10.1016/j.urology.2005.08.053. Urology. 2005. PMID: 16360430

3

Statins, especially atorvastatin, may improve survival following brachytherapy for clinically localized prostate cancer.

Moyad MA, Merrick GS, Butler WM, Wallner KE, Galbreath RW, Butler EG, Allen ZA, Adamovich E. Moyad MA, et al. Urol Nurs. 2006 Aug;26(4):298-303. Urol Nurs. 2006. PMID: 16939047

4

Cholesterol, cholesterol-lowering agents/statins, and urologic disease: Part V--Statins versus aspirin for primary prevention, and the winner is...?

Moyad MA, Merrick GS. Moyad MA, et al. Urol Nurs. 2007 Apr;27(2):166-8. Urol Nurs. 2007. PMID: 17494461

5

Statins and cholesterol lowering after a cancer diagnosis: why not?

Moyad MA, Merrick GS. Moyad MA, et al. Urol Oncol. 2005 Jan-Feb;23(1):49-55. doi: 10.1016/j.urolonc.2005.03.017. Urol Oncol. 2005. PMID: 15885583 Review.

6

Cholesterol, cholesterol lowering agents/statins, and urologic disease: part I - knowing your numbers.

Moyad MA, Merrick GS. Moyad MA, et al. Urol Nurs. 2006 Apr;26(2):156-9. Urol Nurs. 2006. PMID: 16703925 Review.

7

Cholesterol, cholesterol lowering agents/statins, and urologic disease: part II--do you know your Framingham Risk Score?

Moyad MA, Merrick GS. Moyad MA, et al. Urol Nurs. 2006 Jun;26(3):227-9, 203. Urol Nurs. 2006. PMID: 16800331 No abstract available.

8

Cholesterol, cholesterol-lowering agents/statins, and urologic disease: Part VI--The recent rise and fall of the HDL-boosting drug torceptrapib.

Moyad MA, Merrick GS. Moyad MA, et al. Urol Nurs. 2007 Apr;27(2):169-73. Urol Nurs. 2007. PMID: 17494462

9

Cholesterol, cholesterol-lowering agents/statins, and urologic disease: Part III--A rapid review of FDA-approved cholesterol-lowering agents.

Moyad MA, Merrick GS. Moyad MA, et al. Urol Nurs. 2006 Aug;26(4):330-2. Urol Nurs. 2006. PMID: 16939051

10

Lifestyle/dietary supplement partial androgen suppression and/or estrogen manipulation. A novel PSA reducer and preventive/treatment option for prostate cancer?

Moyad MA. Moyad MA. Urol Clin North Am. 2002 Feb;29(1):115-24, ix. doi: 10.1016/s0094-0143(02)00037-x. Urol Clin North Am. 2002. PMID: 12109339 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

126 results

Search Page

Filters